(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.53%.
Mbx Biosciences's earnings in 2026 is -$86,971,000.On average, 13 Wall Street analysts forecast MBX's earnings for 2026 to be -$140,445,029, with the lowest MBX earnings forecast at -$149,457,722, and the highest MBX earnings forecast at -$128,957,053. On average, 13 Wall Street analysts forecast MBX's earnings for 2027 to be -$195,927,491, with the lowest MBX earnings forecast at -$326,851,468, and the highest MBX earnings forecast at -$153,847,669.
In 2028, MBX is forecast to generate -$206,921,361 in earnings, with the lowest earnings forecast at -$323,126,665 and the highest earnings forecast at -$86,801,214.